BPI-1178

DRUG2 trials

Sponsors

Beta Pharma (Suzhou) Co., Ltd., National Cancer Center, China

Conditions

Advanced Solid TumorHR+/HER2- Breast CancerNSCLC

Phase 1

A Study of BPI-1178 in Patients With Advanced Solid Tumor and HR+/HER2- Breast Cancer

RecruitingNCT04282031

Beta Pharma (Suzhou) Co., Ltd.Advanced Solid Tumor, HR+/HER2- Breast Cancer

Start: 2020-06-15End: 2025-06-30Target: 224Updated: 2024-08-07

A Study With BPI-1178 and Osimertinib in Advanced Non-small Cell Lung Cancer Patients With EGFR Mutations

RecruitingNCT06362980

National Cancer Center, ChinaNSCLC

Start: 2024-05-22End: 2026-04-01Target: 20Updated: 2024-07-10

Related Papers

A phase I/IIa study to evaluate the tolerability, safety, pharmacokinetics and efficacy of eciruciclib (BPI-1178) alone in advanced solid tumors and in combination with endocrine therapy for advanced or recurrent HR+/HER2- breast cancer.

Journal of Clinical Oncology2025-05-28